Clinical trials: Mania
Bipolar Disorder
Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine
Inpatient Study Evaluating the Safety and Efficacy of Open-Label Olanzapine Monotherapy in Treatment Refractory Bipolar Mania: This study recruits adult subjects who are diagnosed with Bipolar I Disorder and presently…
- Trial name
- NCT00194064
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University Hospitals Cleveland Medical Center
Treatment-resistant Bipolar Depression
Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression
The overall objective of the investigators is to assess the therapeutic efficacy and tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow for treatment…
- Trial name
- NCT03522545
- Testing
- Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center, Houston
Bipolar Disorder
Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder
The purpose of the trial was to determine whether a 36-ingredient micronutrient supplement (primarily vitamins and minerals) is beneficial for the treatment of bipolar disorder, when studied under randomized and fully blinded…
- Trial name
- NCT00109577
- Testing
- MCN36 (nutritional supplement)
- Where
- 2 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- University of Calgary
Bipolar I Disorder
The Young Adult and Pediatric Bipolar Study
To examine the safety and effectiveness of extended-release carbamazepine in the treatment of children and adolescents aged 10-17 years with acute manic or mixed bipolar I disorder.
- Trial name
- NCT00350857
- Testing
- Extended-Release Carbamazepine
- Where
- 26 sites in United States
- Volunteers
- 161 people
- Sponsor
- Validus Pharmaceuticals
Bipolar Disorder
Cytidine and Omega-3 Fatty Acids in Bipolar Disorder
The goal of the proposed clinical trial is to assess the effect of oral cytidine and omega-3 fatty acids (O3FA) on bipolar disorder symptoms.
- Trial name
- NCT00854737
- Testing
- cytidine, omega-3 fatty acids
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Mclean Hospital
Bipolar Disorder
VALID : VAlproate Versus LIthium in Bipolar Disorders
Primary Objective : To compare the efficacy of valproate to lithium in Bipolar I patients suffering from a manic or a mixed episode according to DSM IV TR (APA 2000) [Diagnostic and Statistical Manual of Mental Disorders (DSM)…
- Trial name
- NCT00264173
- Testing
- Valproate sodium
- Volunteers
- 270 people
- Sponsor
- Sanofi
Bipolar Disorder, Mania
Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar Disorder
This is an 8-week open-label study aimed at assessing the effectiveness and tolerability of Quetiapine, in the treatment of preschool children aged 4 to 6 years with bipolar and bipolar spectrum disorder.
- Trial name
- NCT00181883
- Testing
- quetiapine
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Bipolar Disorder, Schizo Affective Disorder
Causal Lesion Network Guided Treatment of Bipolar Mania With Transcranial Electrical Stimulation
Mania is a core symptom of bipolar disorder involving periods of euphoria. Decreased inhibitory control, increased risk-taking behaviors, and aberrant reward processing are some of the more recognized symptoms of bipolar disorder…
- Trial name
- NCT05445466
- Testing
- High-Definition Transcranial Electrical-Current Stimulation, High-Definition Transcranial Alternate-Current Stimulation, High-Definition Personalized Beta-Gamma Electrical Stimulation
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Beth Israel Deaconess Medical Center
Bipolar Disorder, Schizoaffective Disorder
Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Aim: In a population of first episode manic patients with psychotic features, we want to compare the side effect profile, the degree of adherence and the subjective well being, as well as the efficacy of two treatments: The…
- Trial name
- NCT00202293
- Testing
- Olanzapine, Lithium, Chlorpromazine
- Where
- Australia
- Volunteers
- 83 people
- Sponsor
- Melbourne Health
Acute Bipolar Mania
Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy
The primary objective of this study is to evaluate the broad clinical benefit of dosing Seroquel XR with flexible in the treatment of acute bipolar mania patients with partial response to existing therapy.
- Trial name
- RELEASE (NCT01128114)
- Testing
- Quetiapine fumarate (Seroquel XR)
- Where
- 11 sites in South Korea
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Bipolar Disorder
Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?
This study will evaluate the relative effectiveness of risperidone Consta injections occurring every 2 weeks in contrast to treatment as usual in preventing symptomatic relapse and rates of rehospitalization or admission into…
- Trial name
- Consta (NCT00571688)
- Testing
- Risperdal (risperidone) Consta, Treatment as usual
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt University
Bipolar Disorder, Mania
Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar Disorder
The main objective of this study is to assess the effectiveness and safety of lamotrigine in the treatment of youth with bipolar and bipolar spectrum disorder.
- Trial name
- NCT00181844
- Testing
- lamotrigine
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Massachusetts General Hospital
Bipolar 1 Disorder
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
This is a clinical research study for an investigational drug called RAP-219 in participants with bipolar I disorder. This study is being conducted to determine if RAP-219 is safe and effective in participants experiencing mania…
- Trial name
- NCT07046494
- Testing
- RAP-219
- Where
- 20 sites in United States
- Volunteers
- 253 people
- Sponsor
- Rapport Therapeutics Inc.
Bipolar Disorder
Clozapine for Treatment-Resistant Mania
The purpose of this study is to evaluate the safety and effectiveness of clozapine as a treatment for the manic phase of bipolar disorder.
- Trial name
- NCT00029458
- Testing
- Clozapine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Institute of Mental Health (NIMH)
Bipolar Disorder
A Study Evaluating the Efficacy of Administered Maintenance Treatments in Bipolar Disorder I and II.
The primary objective of the study is to evaluate the efficacy of administered maintenance treatments in bipolar disorder I and II, defined as the percentage of patients who experience a relapse episode during the first 9 months…
- Trial name
- NCT01202604
- Where
- 33 sites in Greece
- Volunteers
- 294 people
- Sponsor
- AstraZeneca
Acute Bipolar Manic Episode
European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes
This study is being carried out to find out how patients suffering from the acute manic phase of bipolar disease are currently managed with Quetiapine Immediate Release (IR) or Quetiapine Extended Release (XR) in the hospital…
- Trial name
- NCT01239589
- Where
- 86 sites in Belgium, Croatia and 6 more
- Volunteers
- 1,280 people
- Sponsor
- AstraZeneca
Bipolar I Disorder
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder
Multicentre, double-blind, randomised, parallel-group, placebo-controlled dose-titration study; depending on clinical efficacy, up-titration of dosage 3 and 6 days after start of treatment; maintenance of individual maximum dose…
- Trial name
- NCT01822678
- Testing
- Eslicarbazepine Acetate
- Volunteers
- 161 people
- Sponsor
- Bial - Portela C S.A.
Healthy
Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes
The purpose of this research is to determine if patients who receive phenytoin (also commonly known as Dilantin) before taking corticosteroids will show less memory impairment and hypomanic symptoms (feelings of agitation…
- Trial name
- NCT00591006
- Testing
- Phenytoin (brand name Dilantin), Hydrocortisone
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Bipolar Disorder, Cannabis-Related Disorder
Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania
The objectives of this study are to determine whether this treatment may be useful for reducing cannabis consumption; reducing symptoms of bipolar mania; and weight mitigation therapy for individuals on psychopharmacotherapy.
- Trial name
- NCT00393978
- Testing
- Quetiapine and Topiramate
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Cincinnati
Memory Loss Associated With Corticosteroid Use, Manic State Associated With Corticosteroid Use
Levetiracetam for Neuroprotection Against Corticosteroid-induced Hippocampal Dysfunction: A Proof of Concept Study
The purpose of this research is to determine whether the memory impairment and manic symptoms (feelings of agitation, overexcitement or hyperactivity) typically seen in those on corticosteroid therapy is decreased with a seizure…
- Trial name
- NCT00223223
- Testing
- Levetiracetam, Keppra
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Texas Southwestern Medical Center